Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlights: Strategic Moves and ... [Yahoo! Finance]
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Cash, Cash Equivalents, and Short-term Investments: $58.5 million as of December 31, 2025. Operating Expenses (Q4 2025): $17.5 million, down from $20.5 million in Q4 2024. Full Year Operating Expenses (2025): $86.9 million, a 23% decrease from $112.6 million in 2024. Net Income (Q4 2025): $3.8 million or $0.06 per share. Net Loss (Full Year 2025): $84.9 million or $1.81 per share. Noncash Gain on Warrant Liability (Q4 2025): $21.2 million. Estimated Cash Runway: Into the fourth-quarter of 2026. Operational Net Cash Burn Estimate (Q1 2026): Approximately $22 million. Headcount Reduction: Approximately 15% to extend cash runway. Warning! GuruFocus has detected 6 Warning Signs with INO. Is INO fairly valued? Test your thesis with our free DCF calculator. Release Date: March 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Inovio Pharmaceutica
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INOGlobeNewswire
- Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire
- INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- INO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026GlobeNewswire
- INO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Inovio Pharmaceuticals, Inc. Securities Lawsuit — The Gross Law FirmGlobeNewswire
INO
Earnings
- 3/12/26 - Beat
INO
Analyst Actions
- 12/30/25 - HC Wainwright
INO
Sec Filings
- 3/12/26 - Form 8-K
- 3/12/26 - Form 10-K
- 3/5/26 - Form 4
- INO's page on the SEC website